Effect of Cyclophosphamide and Prednisone as a First-line Treatment for Non-transplant Candidates with Multiple Myeloma.
- Author:
Mi Ra YOU
1
;
Hyun Jong LIM
;
Hee Jeong LEE
;
Hyung Ho KIM
;
Woo Ram MOON
;
Choon Hae CHUNG
;
Chi Young PARK
;
Sang Gon PARK
Author Information
1. Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University, Gwangju, Korea. SGPARK@chosun.ac.kr
- Publication Type:Original Article
- Keywords:
Multiple myeloma;
Cyclophosphamide;
Melphalan
- MeSH:
Anemia;
Antineoplastic Combined Chemotherapy Protocols;
Cisplatin;
Cyclophosphamide;
Disease-Free Survival;
Humans;
Melphalan;
Methotrexate;
Multiple Myeloma;
Neutropenia;
Prednisone;
Retrospective Studies;
Salvage Therapy;
Thrombocytopenia
- From:Korean Journal of Medicine
2013;84(5):690-697
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: For many years, conventional treatment for multiple myeloma (MM) not ineligible for high-dose therapy has been the combination of oral melphalan and prednisone (MP). However, melphalan-based regimens are associated with numerous complications. Another alkylating agent, cyclophosphamide, has similar effects on MM and is associated with fewer reports of complications. Therefore, cyclophosphamide-based regimens have usually been used as salvage therapy in patients with refractory or relapsed MM, despite the development of newer drugs. The purpose of this report was to evaluate the efficacy and tolerability of cyclophosphamide and prednisone as a first-line therapy for MM. METHODS: For the period January 2002 to June 2012, we retrospectively analyzed 29 patients newly diagnosed with MM who underwent a treatment regimen consisting of intravenous cyclophosphamide (1,000 mg/kg) for 1 day and prednisone (100 mg) for 4 days. RESULTS: The rate of response to this regimen was 31.1 percent. The median progression-free survival (PFS) was 5.5 months and the median overall survival (OS) was 47.3 months. The regimen was well tolerated. Adverse effects of grades above III were as follows: anemia in seven patients (24.1%), neutropenia in five patients (17.2%), and thrombocytopenia in two patients (6.8%). These adverse effects were easily adjusted. No one developed a secondary malignancy or hemorrhagic cystitis. CONCLUSIONS: Although PFS was less than for the MP regimen, median OS was better than for the MP regimen. Furthermore, the cyclophosphamide-prednisone regimen was well tolerated, and the adverse effects that did occur were easily adjusted. The cyclophosphamide-prednisone combination regimen may represent an effective and well tolerated first-line therapy for non-transplant candidates with MM.
